Luxembourg
· Delayed Price · Currency is EUR · Price in USD Oneness Biotech Statistics
Total Valuation
Oneness Biotech has a market cap or net worth of EUR 780.69 million. The enterprise value is 615.17 million.
| Market Cap | 780.69M |
| Enterprise Value | 615.17M |
Important Dates
The next estimated earnings date is Tuesday, May 13, 2025.
| Earnings Date | May 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.97% |
| Shares Change (QoQ) | +0.07% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 308.47M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 224.67 |
| PB Ratio | 2.07 |
| P/TBV Ratio | 2.38 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -17.92 |
| EV / Sales | 192.61 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -52.82 |
Financial Position
The company has a current ratio of 39.87, with a Debt / Equity ratio of 0.03.
| Current Ratio | 39.87 |
| Quick Ratio | 38.90 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.03 |
| Interest Coverage | -113.02 |
Financial Efficiency
Return on equity (ROE) is -8.45% and return on invested capital (ROIC) is -4.83%.
| Return on Equity (ROE) | -8.45% |
| Return on Assets (ROA) | -4.68% |
| Return on Invested Capital (ROIC) | -4.83% |
| Return on Capital Employed (ROCE) | -8.06% |
| Revenue Per Employee | 80,810 |
| Profits Per Employee | -798,427 |
| Employee Count | 43 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0.46 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -62.61% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -62.61% |
| 50-Day Moving Average | 11.02 |
| 200-Day Moving Average | 17.82 |
| Relative Strength Index (RSI) | 42.49 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Oneness Biotech had revenue of EUR 3.47 million and -34.33 million in losses. Loss per share was -0.07.
| Revenue | 3.47M |
| Gross Profit | 1.86M |
| Operating Income | -32.00M |
| Pretax Income | -33.88M |
| Net Income | -34.33M |
| EBITDA | -20.07M |
| EBIT | -32.00M |
| Loss Per Share | -0.07 |
Balance Sheet
The company has 206.82 million in cash and 11.97 million in debt, giving a net cash position of 194.85 million.
| Cash & Cash Equivalents | 206.82M |
| Total Debt | 11.97M |
| Net Cash | 194.85M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 377.16M |
| Book Value Per Share | 0.76 |
| Working Capital | 209.51M |
Cash Flow
In the last 12 months, operating cash flow was -10.18 million and capital expenditures -1.46 million, giving a free cash flow of -11.65 million.
| Operating Cash Flow | -10.18M |
| Capital Expenditures | -1.46M |
| Free Cash Flow | -11.65M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 53.45% |
| Operating Margin | -920.96% |
| Pretax Margin | -974.96% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Oneness Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.97% |
| Shareholder Yield | -0.97% |
| Earnings Yield | -4.40% |
| FCF Yield | -1.49% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Oneness Biotech has an Altman Z-Score of 48.44.
| Altman Z-Score | 48.44 |
| Piotroski F-Score | n/a |